May 2022: Trametinib inogona kuve chiyero chitsva chekutarisira inodzokororwa, yakaderera-giredhi serous ovarian cancer (Mekinist). Zvinoenderana nezvakawanikwa muongororo yakaburitswa muna Kukadzi 2022 chinyorwa cheThe Lancet, trametinib yakarova zvese chemotherapy uye anti-estrogens setamoxifen nezvikamu makumi mashanu neshanu muzana, ichiwedzera mwedzi mitanhatu yekufambira mberi-isina (nguva iyo gomarara risina kufambira mberi) kupona kwevarwere.
Mune 260 vakadzi vane adzokororwa serous ovarian tumors avo vakambogamuchira chemotherapy, vaongorori kubva kuUnited States neUnited Kingdom vakafananidza kamwe-zuva nezuva trametinib yemuromo kune imwe yemashanu maitiro ekuchengeta regimens (ingave chemotherapy kana anti-estrogen mishonga). Kana ichienzaniswa neyakajairwa kurapwa, vatori vechikamu ve trametinib vakaratidza mhinduro yakapetwa kana pakurapa mushure memwedzi ye15. Trametinib yakapfuura mamwe marapirwo ese, ichinonotsa kufambira mberi kwechirwere kwemwedzi gumi nemitatu (zvichienderana nemwedzi minomwe yekurapa kwakajairwa). Ganda repundu, kupererwa neropa, BP, manyoka, uye kuneta ndezvimwe zvezvingangove zvine ngozi zvinokonzeresa kurapwa kwetrametinib.
Low-grade serous ovarian kenza is a difficult-to-treat invasive form of ovarian cancer marked by strong hormone receptor activation, genetic alterations, and poor chemotherapy response. Until now, the cancer toolbox lacked effective therapeutic options for patients with low-grade serous ovarian cancer. According to an editorial accompanying the report, 70% of these women will recur, with only 5% responding to further chemotherapy.
